{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=82", "query": { "intervention": "Protein Control", "page": 82 }, "page_size": 10 }, "pagination": { "page": 82, "page_size": 10, "total_count": 3500, "total_pages": 350, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=83&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=81&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T18:15:12.695Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04824092", "title": "Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Tafasitamab placebo", "type": "DRUG" }, { "name": "Lenalidomide placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 899, "start_date": "2021-05-11", "completion_date": "2027-11-01", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-11-07T18:15:12.695Z", "location_count": 47, "location_summary": "Daphne, Alabama • Anaheim, California • Clovis, California + 44 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Clovis", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Harbor City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04824092" }, { "nct_id": "NCT06500637", "title": "TB006 for Autism Spectrum Disorder", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autism Spectrum Disorder" ], "interventions": [ { "name": "TB006", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rossignol Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "18 Years to 35 Years" }, "enrollment_count": 45, "start_date": "2024-08-03", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-11-07T18:15:12.695Z", "location_count": 2, "location_summary": "Phoenix, Arizona • Aliso Viejo, California", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Aliso Viejo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06500637" }, { "nct_id": "NCT00430495", "title": "A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Atacicept", "type": "DRUG" }, { "name": "Placebo matched to atacicept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 256, "start_date": "2006-12", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2016-02-17", "last_synced_at": "2026-11-07T18:15:12.695Z", "location_count": 1, "location_summary": "Rockland, Massachusetts", "locations": [ { "city": "Rockland", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00430495" }, { "nct_id": "NCT03285412", "title": "CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Endocrine therapy", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 120, "start_date": "2017-12-12", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2025-12-22", "last_synced_at": "2026-11-07T18:15:12.695Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Danvers, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Danvers", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03285412" }, { "nct_id": "NCT03595553", "title": "Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clostridioides Difficile Infection" ], "interventions": [ { "name": "Ridinilazole", "type": "DRUG" }, { "name": "Vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Summit Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 759, "start_date": "2019-01-28", "completion_date": "2021-11-17", "has_results": true, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-11-07T18:15:12.695Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Sun City, Arizona • Los Angeles, California + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Redding", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03595553" }, { "nct_id": "NCT05376319", "title": "PR3-AAV Resilient Remission or PRRR", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Granulomatosis With Polyangiitis", "Microscopic Polyangiitis", "ANCA Associated Vasculitis" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-06-30", "completion_date": "2024-05-07", "has_results": true, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-11-07T18:15:12.695Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Rochester, Minnesota • Philadelphia, Pennsylvania", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05376319" }, { "nct_id": "NCT03434119", "title": "Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin glargine/Lixisenatide", "type": "DRUG" }, { "name": "Insulin glargine (HOE901)", "type": "DRUG" }, { "name": "Background therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 241, "start_date": "2018-02-20", "completion_date": "2019-01-07", "has_results": true, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-11-07T18:15:12.695Z", "location_count": 85, "location_summary": "Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03434119" }, { "nct_id": "NCT05142722", "title": "Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dyslipidemias", "High Cholesterol", "Hypercholesterolemia", "Familial Hypercholesterolemia", "Atherosclerotic Cardiovascular Disease" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Obicetrapib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NewAmsterdam Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2530, "start_date": "2021-12-15", "completion_date": "2024-09-26", "has_results": true, "last_update_posted_date": "2025-09-19", "last_synced_at": "2026-11-07T18:15:12.695Z", "location_count": 69, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Saraland, Alabama + 60 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Saraland", "state": "Alabama" }, { "city": "Sheffield", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT05142722" }, { "nct_id": "NCT02597660", "title": "A Study to Evaluate the Efficacy of Somatropin in the Treatment of Patellar Tendinopathy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tendinopathy" ], "interventions": [ { "name": "Somatropin", "type": "DRUG" }, { "name": "Bacteriostatic saline", "type": "DRUG" }, { "name": "Progressive exercise program", "type": "OTHER" }, { "name": "Patellar tendon biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Hospital for Special Surgery, New York", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 0, "start_date": "2020-05-01", "completion_date": "2020-12-01", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-11-07T18:15:12.695Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02597660" }, { "nct_id": "NCT00168779", "title": "Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "telmisartan 80 mg / hydrochlorothiazide 25 mg", "type": "DRUG" }, { "name": "valsartan 160 mg / hydrochlorothiazide 25 mg", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1185, "start_date": "2005-09", "completion_date": "2006-07", "has_results": false, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-11-07T18:15:12.695Z", "location_count": 113, "location_summary": "Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 90 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00168779" } ] }